Literature DB >> 31003979

Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis.

Sara Lemoinne1,2,3, Astrid Kemgang1,2,3, Karima Ben Belkacem1,2,3, Marjolène Straube1,4, Sarah Jegou1,4, Christophe Corpechot1,2,3, Olivier Chazouillères1,2,3, Chantal Housset1,2,3, Harry Sokol1,4,5.   

Abstract

OBJECTIVE: Patients with primary sclerosing cholangitis (PSC) were previously shown to display a bacterial gut dysbiosis but fungal microbiota has never been examined in these patients. The aim of this study was to assess the fungal gut microbiota in patients with PSC.
DESIGN: We analysed the faecal microbiota of patients with PSC and concomitant IBD (n=27), patients with PSC and no IBD (n=22), patients with IBD and no PSC (n=33) and healthy subjects (n=30). Bacterial and fungal composition of the faecal microbiota was determined using 16S and ITS2 sequencing, respectively.
RESULTS: We found that patients with PSC harboured bacterial dysbiosis characterised by a decreased biodiversity, an altered composition and a decreased correlation network density. These alterations of the microbiota were associated with PSC, independently of IBD status. For the first time, we showed that patients with PSC displayed a fungal gut dysbiosis, characterised by a relative increase in biodiversity and an altered composition. Notably, we observed an increased proportion of Exophiala and a decreased proportion of Saccharomyces cerevisiae. Compared with patients with IBD and healthy subjects, the gut microbiota of patients with PSC exhibited a strong disruption in bacteria-fungi correlation network, suggesting an alteration in the interkingdom crosstalk.
CONCLUSION: This study demonstrates that bacteria and fungi contribute to gut dysbiosis in PSC. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  fungi; gut microbiota; inflammatory bowel disease; primary sclerosing cholangitis

Year:  2019        PMID: 31003979     DOI: 10.1136/gutjnl-2018-317791

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  42 in total

Review 1.  Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?

Authors:  Lu Jiang; Bernd Schnabl
Journal:  Physiology (Bethesda)       Date:  2020-07-01

2.  The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease.

Authors:  Huikuan Chu; Yi Duan; Sonja Lang; Lu Jiang; Yanhan Wang; Cristina Llorente; Jinyuan Liu; Selene Mogavero; Francisco Bosques-Padilla; Juan G Abraldes; Victor Vargas; Xin M Tu; Ling Yang; Xiaohua Hou; Bernhard Hube; Peter Stärkel; Bernd Schnabl
Journal:  J Hepatol       Date:  2019-10-10       Impact factor: 25.083

Review 3.  Gut Mycobiota in Immunity and Inflammatory Disease.

Authors:  Xin V Li; Irina Leonardi; Iliyan D Iliev
Journal:  Immunity       Date:  2019-06-18       Impact factor: 31.745

Review 4.  Intestinal virome and therapeutic potential of bacteriophages in liver disease.

Authors:  Cynthia L Hsu; Yi Duan; Derrick E Fouts; Bernd Schnabl
Journal:  J Hepatol       Date:  2021-08-24       Impact factor: 25.083

Review 5.  Roles for the mycobiome in liver disease.

Authors:  Suling Zeng; Bernd Schnabl
Journal:  Liver Int       Date:  2022-01-17       Impact factor: 5.828

6.  The fecal mycobiome in non-alcoholic fatty liver disease.

Authors:  Münevver Demir; Sonja Lang; Phillipp Hartmann; Yi Duan; Anna Martin; Yukiko Miyamoto; Marina Bondareva; Xinlian Zhang; Yanhan Wang; Philipp Kasper; Corinna Bang; Christoph Roderburg; Frank Tacke; Hans-Michael Steffen; Tobias Goeser; Andrey Kruglov; Lars Eckmann; Peter Stärkel; Derrick E Fouts; Bernd Schnabl
Journal:  J Hepatol       Date:  2021-12-10       Impact factor: 25.083

Review 7.  The impact of the Fungus-Host-Microbiota interplay upon Candida albicans infections: current knowledge and new perspectives.

Authors:  Christophe d'Enfert; Ann-Kristin Kaune; Leovigildo-Rey Alaban; Sayoni Chakraborty; Nathaniel Cole; Margot Delavy; Daria Kosmala; Benoît Marsaux; Ricardo Fróis-Martins; Moran Morelli; Diletta Rosati; Marisa Valentine; Zixuan Xie; Yoan Emritloll; Peter A Warn; Frédéric Bequet; Marie-Elisabeth Bougnoux; Stephanie Bornes; Mark S Gresnigt; Bernhard Hube; Ilse D Jacobsen; Mélanie Legrand; Salomé Leibundgut-Landmann; Chaysavanh Manichanh; Carol A Munro; Mihai G Netea; Karla Queiroz; Karine Roget; Vincent Thomas; Claudia Thoral; Pieter Van den Abbeele; Alan W Walker; Alistair J P Brown
Journal:  FEMS Microbiol Rev       Date:  2021-05-05       Impact factor: 16.408

Review 8.  Gut microbiome, liver immunology, and liver diseases.

Authors:  Rui Wang; Ruqi Tang; Bo Li; Xiong Ma; Bernd Schnabl; Herbert Tilg
Journal:  Cell Mol Immunol       Date:  2020-12-14       Impact factor: 11.530

9.  Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis.

Authors:  Martin Kummen; Louise B Thingholm; Malte C Rühlemann; Kristian Holm; Simen H Hansen; Lucas Moitinho-Silva; Timur Liwinski; Roman Zenouzi; Christopher Storm-Larsen; Øyvind Midttun; Adrian McCann; Per M Ueland; Marte L Høivik; Mette Vesterhus; Marius Trøseid; Matthias Laudes; Wolfgang Lieb; Tom H Karlsen; Corinna Bang; Christoph Schramm; Andre Franke; Johannes R Hov
Journal:  Gastroenterology       Date:  2020-12-31       Impact factor: 22.682

10.  Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis.

Authors:  Xiuting Hu; Wei Cheng; Shengxian Fan; Yuhua Huang; Xi Chen; Zhiwei Jiang; Jian Wang
Journal:  BMC Infect Dis       Date:  2021-06-16       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.